The Medical Briefing Nephrology
Sibeprenlimab in IgA nephropathy, CAR-T and AKI, anticoagulation in advanced CKD, FIND-CKD
Retrospective no. 4/12
The essentials in four articles
■ Glomerular disease
Phase 3, 510 patients, sibeprenlimab 400 mg every 4 weeks for 24 months: annual GFR slope +0.3 vs −4.2 mL/min/1.73 m²/year and major kidney events 0.4% vs 11.2%. Favorable tolerability at 24 months.
■ AKI and critical care
186 patients treated with CAR-T: AKI in 34%, nearly 78% within the first three weeks. CKD and prior AKI increase the risk; AKI is associated with higher mortality (adjusted HR 2.59).
■ CKD and dialysis
1,458 patients with stage 4–5 CKD or dialysis: rivaroxaban 2.5 mg twice daily does not reduce major cardiovascular events (HR 1.09) and increases major bleeding (HR 1.51). Trial stopped early for futility.
■ CKD and dialysis
1,584 patients with non-diabetic albuminuric CKD: GFR slope −3.3 vs −4.0 mL/min/1.73 m²/year on finerenone, albuminuria −41.3% at 6 months, hyperkalemia 17.0% vs 13.3%.